COMPARISON
Calcitonin vs Insulin degludec
6 attributes held for at least one of the two. 6 differ. Each value carries the register it came from and the date that register was read.
Answer
Calcitonin is authorised or registered in 8 and Insulin degludec in 10 of the 10 registers read. Calcitonin: highest phase Phase 4 (after approval). Insulin degludec: highest phase Phase 4 (after approval). 0 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Calcitonin | Insulin degludec | |
|---|---|---|
| Registered trials differs | 154 clinicaltrials.gov · 2026-10-03 | 255 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: CALCITONIN SALMON openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Xultophy 100/3.6 openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Withdrawn ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | Not checked no record of "authorisedOn" for calcitonin | 2013-01-20 ema · 2026-10-03 |
| EU withdrawn on differs | 2008-11-20 ema · 2026-10-03 | Not checked no record of "withdrawnOn" for insulin-degludec |
| ATC code differs | H05BA01 ema · 2026-10-03 | A10AE06 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Calcitonin | placebo | Insulin degludec | placebo |
|---|---|---|---|---|
| Hot flush | 16.9% | 4.3% | - | - |
| Arthralgia | 16.5% | 21.9% | - | - |
| Nausea | 14.8% | 3.0% | - | - |
| Back Pain | 10.0% | 10.6% | - | - |
| Dyspepsia | 9.2% | 4.1% | - | - |
| Diarrhoea | 8.7% | 5.3% | - | - |
| Influenza | 7.0% | 6.9% | - | - |
| Nasopharyngitis | 6.8% | 8.0% | - | - |
| Dizziness | 6.2% | 3.3% | - | - |
| Hypertension | 6.0% | 7.7% | - | - |
Trial register Calcitonin: 2 placebo-controlled trials; Insulin degludec: 0. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Calcitonin side effects · Insulin degludec side effects
LEGAL STATUS
Approval in each country read
| Country | Calcitonin | Insulin degludec | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Withdrawn | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Not on the register | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.